Arax Advisory Partners’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$29.5K Buy
502
+403
+407% +$16.9K ﹤0.01% 3687
2026
Q1
$3.19K Sell
99
-26
-21% -$962 ﹤0.01% 2965
2025
Q4
$5.26K Sell
125
-117
-48% -$4.72K ﹤0.01% 2818
2025
Q3
$8.31K Buy
242
+219
+952% +$6.28K ﹤0.01% 2674
2025
Q2
$622 Sell
23
-11
-32% -$319 ﹤0.01% 2900
2025
Q1
$1.01K Buy
34
+17
+100% +$648 ﹤0.01% 2301
2024
Q4
$674 Sell
17
-2
-11% -$76 ﹤0.01% 2260
2024
Q3
$647 Sell
19
-15
-44% -$422 ﹤0.01% 2363
2024
Q2
$737 Buy
34
+1
+3% +$21 ﹤0.01% 2253
2024
Q1
$730 Hold
33
﹤0.01% 1201
2023
Q4
$909 Buy
33
+9
+38% +$217 ﹤0.01% 1146
2023
Q3
$536 Hold
24
﹤0.01% 1234
2023
Q2
$612 Hold
24
﹤0.01% 1181
2023
Q1
$535 Hold
24
﹤0.01% 1183
2022
Q4
$570 Buy
+24
New +$558 ﹤0.01% 1165
2022
Q2
Sell
-20
Closed -$1K 1246
2022
Q1
$1K Hold
20
﹤0.01% 1108
2021
Q4
$1K Buy
+20
New +$884 ﹤0.01% 1099

Other funds holding VCYT

Arax Advisory Partners's VCYT Position: Q2 2026 in Review

Arax Advisory Partners increased its Veracyte (VCYT) stake by 407% in Q2 2026, buying an estimated $16.9K and bringing the position to 502 shares worth $29.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3687.

Arax Advisory Partners first reported a position in VCYT in Q4 2021 and has held it in 17 quarters since. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Arax Advisory Partners held 502 shares of Veracyte worth $29.5K as of Q2 2026.
  • Arax Advisory Partners bought 403 Veracyte shares in Q2 2026, an estimated $16.9K.
  • Veracyte made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3687 holding.
  • Arax Advisory Partners first reported a position in Veracyte in Q4 2021 and has held it in 17 quarters since.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.